To Be Discontinued Tablet Neurology

Divalproex Sodium Tablet, De · 501 days since initial FDA posting

Brand: DIVALPROEX SODIUM

FDA lists Divalproex Sodium Tablet, De as To Be Discontinued (Upsher-Smith Laboratories, LLC).

No availability text on this FDA row.

Divalproex Sodium Tablet, Delayed Release: To Be Discontinued

FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.

Shortage Details

Generic Name
Divalproex Sodium Tablet, Delayed Release
Manufacturer
Upsher-Smith Laboratories, LLC
Dosage Form
Tablet
Presentation
Divalproex Sodium, Tablet, Delayed Release, 125 mg (NDC 0832-7122-15)
Package NDC
0832-7122-15

Status & Timeline

Status
To Be Discontinued
First Reported
Apr 28, 2025
Last Updated
Apr 28, 2025
Therapeutic Category
Neurology

Row fields from the FDA Drug Shortages database via openFDA.

Shortage Reason

Discontinuation of manufacture of drug based on business decision.

Nearby, Other Divalproex Shortage Records

Divalproex Sodium Tablet, Delayed Release

Upsher-Smith Laboratories, LLC

Tablet

To Be Discontinued

Divalproex Sodium Tablet, Delayed Release

Upsher-Smith Laboratories, LLC

Tablet

To Be Discontinued

Divalproex Sodium Tablet, Delayed Release

Upsher-Smith Laboratories, LLC

Tablet

To Be Discontinued

Divalproex Sodium Tablet, Delayed Release

Upsher-Smith Laboratories, LLC

Tablet

To Be Discontinued

Divalproex Sodium Tablet, Delayed Release

Upsher-Smith Laboratories, LLC

Tablet

To Be Discontinued

Divalproex Sodium Tablet, Delayed Release

Upsher-Smith Laboratories, LLC

Tablet

To Be Discontinued

FDA reason on file: Discontinuation of manufacture of drug based on business decision. General shortage guidance lives on the tracker hub.

← All Drug Shortages